“Efficacy of Rifaximin in Diarrhoea Predominant Irritable Bowel Syndrome: A Placebo Controlled Clinical Trial” (2023) Medicine Today, 35(1), pp. 44–48. doi:10.3329/medtoday.v35i1.64940.